Melanoma incidence and exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers

Cancer Epidemiology

Volumn 33, Issue 5, 2009, Pages 391-395

  Koomen, E R ^a   Herings, R M C ^b   Guchelaar, H J ^a   Nijsten, T ^c  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b PHARMO   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

ACE inhibitors; Angiotensin II type 1 receptor Antagonists; Angiotensin converting enzyme inhibitors; Melanoma

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BENAZEPRIL; CAPTOPRIL; CILAZAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; LISINOPRIL; MOEXIPRIL; PERINDOPRIL; QUINAPRIL; RAMIPRIL; SPIRAPRIL; TRANDOLAPRIL; ZOFENOPRIL;

ADULT; AGED; ARTICLE; CANCER INCIDENCE; CANCER RISK; CONTROLLED STUDY; DRUG USE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MELANOMA; PRIORITY JOURNAL; SKIN CARCINOGENESIS;

ADOLESCENT; ADULT; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; FEMALE; HUMANS; INCIDENCE; MALE; MELANOMA; MIDDLE AGED; SKIN NEOPLASMS; YOUNG ADULT;

EID: 70649086970     PISSN: 18777821     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canep.2009.10.005     Document Type: Article

References (17)

1. Lindberg L., Nielsen D., Jensen B.V., Eriksen J., and Skovsgaard T. Angiotensin converting enzyme inhibitors for cancer treatment?. Acta Oncologica 43 2 (2004) 142-152
2. Chen L., Re R.N., Prakash O., and Mondal D. Angiotensin-converting enzyme inhibition reduces neuroblastoma cell growth rate. Proc Soc Exp Biol Med 196 (1991) 280-283
3. Yoshiji H., Kuriyama S., Kawata M., Yoshii J., Ikenaka Y., Noguchi R., et al. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res 7 (2001) 1073-1078
4. Volpert O.V., Ward W.F., Lingen M.W., Chesler L., Solt D.B., Johnson M.D., et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 98 (1996) 671-679
5. Yasumatsu R., and Nakashima T. Effects of the angiotensin-1 converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells. J Cancer Res Clin Oncol 130 (2004) 567-573
6. Friis S., Sorensen H.T., Mellemkjaer L., MacLaughlin J.K., Nielsen G.L., Blot W.J., et al. Angiotensis-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer 92 (2001) 2462-2470
7. White C.M. Angiotensin-converting enzyme inhibition in heart failure or after myocardial infarction. Am J Health-Syst Pharm 57 (2000) S18-S25
8. Gately S., Twardowski P., Stack M.S., Cundiff D.L., Grella D., Castellino F.J., et al. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci USA 94 (1997) 10868-10872
9. Wartenberg M., Budde P., de Mareés M., Grünheck F., Tsang S.Y., Hang Y., et al. Inhibition of tumor-induced angiogenesis and matrix-metalloproteinase expression in confrontation cultures of embryoid bodies and tumor spheroids by plant ingredients used in traditional Chinese medicine. Lab Invest 83 (2003) 87-98
10. Groot, de-Besseling R.R.J., Ruers T.J.M., van Kraats A.A., Poelen G.J.M., Ruiter D.J., et al. Anti-tumor activity of a combination of plasminogen activator and captopril in a human melanoma xenograft model. Int J Cancer 112 (2004) 329-334
11. Eigentler T.K., Caroli U.M., Radny P., and Garbe C. Palliative therapy of disseminated malignant melanoma: a systematic review of 41 randomized clinical trials. Lancet Oncol 4 (2003) 748-759
12. Christian J.B., Lapane K.L., Hume A.L., Eaton C.B., and Weinstock M.A. Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial. J Natl Cancer Inst 100 (2008) 1223-1232
13. Koomen E.R., Joosse A., Herings R.M.C., Casparie M.K., Bergman W., Nijsten T., et al. Is statin use associated with a reduced incidence, reduced Breslow thickness or delayed metastasis of melanoma of the skin?. Eur J Cancer 43 (2007) 2580-2589
14. Herings R, Pharmo, a record linkage system for post marketing surveillance of prescription drugs in the Netherlands. In: Thesis in pharmaco-epidemiology and pharmacotherapy. The Netherlands, Utrecht University, 1993:17-32.
15. Van Herk-Sukel MPP, van de Poll-Franse LV, Lemmens VEPP, Vreugdenhil G, Pruijt JFM, Coebergh JWW, et al. New opportunities for drug outcomes research in cancer patients: the linkage of the Eindhoven Cancer Registry and the PHARMO record linkage system. Eur J Cancer (in press).
16. Freeman S.R., Drake A.L., Heilig L.F., Graber M., McNealy K., Schilling L.M., et al. Statins, fibrates, and melanoma risk: a systematic review and meta-analysis. J Natl Cancer Inst 98 21 (2006) 1538-1546
17. Vandenbroucke J.P., Von Elm E., Altman D.G., Gøtzsche P.C., Mulrow C.D., Pocock S.J., et al. Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Ann Intern Med 147 (2007) 163-194